Petrylak, D. P., Ratta, R., Matsubara, N., Korbenfeld, E. P., Gafanov, R., Mourey, L., … Fizazi, K. (2023). Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Gafanov, Loic Mourey, Tilman Todenhofer, et al. “Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Petrylak, Daniel P., et al. “Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.

Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, Todenhofer T, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen WR, Pachynski RK, Byun S-S, Li XT, Schloss C, Poehlein CH, Fizazi K. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. JOURNAL OF CLINICAL ONCOLOGY. 2023.